5378-27-8

Usage

Uses

Used in Pharmaceutical Industry:
4-(1,3,4-OXADIAZOL-2-YL)PHENOL, 95+% is used as an intermediate in the synthesis of potential class II human histone deacetylase inhibitors. These inhibitors play a crucial role in the development of drugs for the treatment of various diseases, including cancer, by modulating the activity of histone deacetylases, which are enzymes involved in the regulation of gene expression.

InChI:InChI=1/C8H6N2O2/c11-7-3-1-6(2-4-7)8-10-9-5-12-8/h1-5,10H

Upstream product

• 5351-23-5 4-hydroxybenzoic acid hydrazide 
• 122-51-0 orthoformic acid triethyl ester 
• 956750-65-5 2-(4-(benzyloxy)phenyl)-1,3,4-oxadiazole 
• 99-76-3 methyl 4-hydroxylbenzoate 
• 99-96-7 4-hydroxy-benzoic acid 
• 120-47-8 Ethyl 4-hydroxybenzoate 
• 75-52-5 nitromethane 
• 1895-39-2 sodium chlorodifluoroacetate 

Downstream Products

• 97663-41-7 I-125 2-(3,5-diiodo-4-hydroxyphenyl)-1,3,4-oxadiazole 
• 31963-93-6 2-(3,5-diiodo-4-hydroxyphenyl)-1,3,4-oxadiazole 
• 420122-33-4 2-[4-(4-Methoxy-phenoxy)-phenyl]-[1,3,4]oxadiazole 
• 214342-28-6 (2R)-1-(4-[1,3,4]-Oxadiazol-2-ylphenoxy)-4-pyridin-3-yl-butan-2-ol 
• 767-00-0 4-cyanophenol 
• 97663-43-9 4-[(4-Hydroxy-3,5-diiodo-benzoyl)-hydrazonomethyl]-benzoic acid 

Relevant academic research and scientific papers

[4u202f+u202f1] Cyclization of benzohydrazide and ClCF2COONa towards 1,3,4-oxadiazoles and 1,3,4-oxadiazoles-d5

A facile synthesis of 1,3,4-oxadiazoles and 1,3,4-oxadiazoles-d5 via [4 + 1] cyclization of ClCF2COONa with non-amine compounds containing amino groups is developed. Of note, this is the first time that halofluorinated compounds are used as C1 synthon to construct deuterated nitrogen-heterocyclic compounds. The current protocol features simple operation, readily accessible raw materials, wide substrate scope and valuable products

Ligand-Enabled Palladium-Catalyzed Through-Space C?H Bond Activation via a Carbopalladation/1,4-Pd Migration/C?H Functionalization Sequence

We report, herein, a palladium-catalyzed cascade comprising carbopalladation, 1,4-Pd-migration and C(sp2)?C(sp2) bond formation to construct a variety of bis-heterocyclic frameworks in a single operational step. The methodology provi

Electrophilic activation of nitroalkanes in efficient synthesis of 1,3,4-oxadiazoles

A novel methodology for general and chemoselective preparation of non-symmetric 1,3,4-oxadiazoles is developed. This unusual reaction proceeds via polyphosphoric acid-assisted activation of nitroalkanes towards nucleophilic attack with acylhydrazides.

Design, synthesis and biological evaluation of 2-(phenoxymethyl)-5-phenyl-1,3,4-oxadiazole derivatives as anti-breast cancer agents

Structural based molecular docking approach revealed the findings of 2-(phenoxymethyl) -5-phenyl-1,3,4-oxadiazole derivatives. The compounds (7a-o) were synthesized and characterized well by using conventional methods. The compounds, 7b and 7m were reconfirmed through single crystal XRD analysis. The synthesized compounds (7a-o) were evaluated their antiproliferative activities against MCF-7 and MDA-MB-453. Furthermore, Lipinski's rule of five and pharmacokinetic properties were predicted for the test compounds. These results demonstrate that the compounds 7b and 7d exhibit more potent cytotoxicity and 7d exhibits dose-dependent activity and reduced cell viability. Further, the mechanism of action for the induced apoptosis was observed through morphological changes and western blotting analysis. These findings may furnish the lead for further development.

Design and synthesis of tailored human caseinolytic protease P inhibitors

Human caseinolytic protease P (hClpP) is important for degradation of misfolded proteins in the mitochondrial unfolded protein response. We here introduce tailored hClpP inhibitors that utilize a steric discrimination in their core naphthofuran scaffold to selectively address the human enzyme. This novel inhibitor generation exhibited superior activity compared to previously introduced beta-lactones, optimized for bacterial ClpP. Further insights into the bioactivity and binding to cellular targets were obtained via chemical proteomics as well as proliferation- and migration studies in cancer cells.

BICYCLIC HETEROARYL COMPOUNDS AS PDE10 INHIBITORS

The invention pertains to tricyclic heteraaryi compounds that serve as effective phosphodiesterase (PDE) inhibitors. The invention also relates to compounds which are selective inhibitors of PDE 10. The invention further relates to pharmaceutical compositions comprising such compounds; and the use of such compounds in methods for treating certain central nervous system (CNS) or other disorders. The invention relates also to methods for treating neurodegenerative and psychiatric disorders, for example psychosis and disorders comprising deficient cognition as a symptom.

Heterocyclic derivatives of (4-aryloxy-methyl-1,3-dioxolan-2-yl)methyl-1H-imidazoles and 1H-1,2,4-triazoles

Novel heterocyclic derivatives of (4-aryloxymethyl-1,3-dioxolan-2-yl)methyl-1H-imidazoles and 1H-1,2,4-triazoles, useful as antifungal and antibacterial agents.